1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-115.67%
Negative EBIT growth while AVXL is at 19.61%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-115.67%
Negative operating income growth while AVXL is at 19.61%. Joel Greenblatt would press for urgent turnaround measures.
-133.51%
Negative net income growth while AVXL stands at 19.80%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-132.80%
Negative EPS growth while AVXL is at 20.83%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-132.80%
Negative diluted EPS growth while AVXL is at 17.39%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
31.94%
Positive OCF growth while AVXL is negative. John Neff would see this as a clear operational advantage vs. the competitor.
31.94%
Positive FCF growth while AVXL is negative. John Neff would see a strong competitive edge in net cash generation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-162.45%
Both show negative 10Y OCF/share CAGR. Martin Whitman would question if the entire market or product set is shrinking or too capital-intensive.
-162.45%
Both show negative mid-term OCF/share growth. Martin Whitman might suspect a challenged environment or large capital demands for both.
-162.45%
Both face negative short-term OCF/share growth. Martin Whitman would suspect macro or cyclical issues hitting them both.
-7367.52%
Both face negative decade-long net income/share CAGR. Martin Whitman would suspect a shrinking or highly disrupted sector.
-7367.52%
Both exhibit negative net income/share growth over five years. Martin Whitman would suspect a challenging environment for the entire niche.
-7367.52%
Both companies show negative 3Y net income/share growth. Martin Whitman suspects macro or sector-specific headwinds in the short run.
-772.82%
Negative equity/share CAGR over 10 years while AVXL stands at 0.00%. Joel Greenblatt sees a fundamental red flag unless the competitor also struggles.
-772.82%
Negative 5Y equity/share growth while AVXL is at 0.00%. Joel Greenblatt sees the competitor building net worth while this firm loses ground.
-772.82%
Negative 3Y equity/share growth while AVXL is at 0.00%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-64.40%
Negative asset growth while AVXL invests at 522228.00%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
-61.26%
We have a declining book value while AVXL shows 21.66%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
8.45%
Debt growth of 8.45% while AVXL is zero. Bruce Berkowitz sees additional leverage that must yield profitable expansions to be worthwhile.
No Data
No Data available this quarter, please select a different quarter.
-27.70%
We cut SG&A while AVXL invests at 178.28%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.